Outlook Therapeutics, Inc. Common Stock
Here’s whether Outlook Therapeutics, Inc. Common Stock (OTLK) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+25.97% over 10 days); 3-month momentum positive (+73.5%). Concerns: trading below the 200-day MA (long-term downtrend); RSI 87 — overbought, elevated pullback risk; weak 1-year return of -58.5%; rising volume on a downtrend (distribution, 2.62x avg). Currently 77.1% off its 52-week high. Score: -1/7.
OTLK is trading below its 200-day MA ($0.91) — a key warning sign the longer-term trend is under pressure. With an RSI of 86.6, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -58.5% compares to +24.4% for SPY (trailed the market by 82.8%). The current 77.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.